Trial Profile
An Extension Study of Navitoclax (ABT-263) in Subjects With Chronic Lymphocytic Leukemia (CLL)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Jul 2016
Price :
$35
*
At a glance
- Drugs Navitoclax (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions
- Sponsors AbbVie
- 01 Jul 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 13 Mar 2013 Planned End Date changed from 1 Jun 2013 to 1 Jul 2013 as reported by ClinicalTrials.gov.
- 12 Mar 2013 New trial record